Cargando…

Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis

The main aim of this study is to investigate whether baseline lactate dehydrogenase (LDH) is associated with the clinical outcome of non small‐cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). We searched Pubmed, the Cochrane Central library and Embase for periphera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhibo, Li, Ye, Yan, Xiang, Song, Qi, Wang, Guoqiang, Hu, Yi, Jiao, Shunchang, Wang, Jinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488146/ https://www.ncbi.nlm.nih.gov/pubmed/30848091 http://dx.doi.org/10.1002/cam4.2024

Ejemplares similares

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2016)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Zhang, Zhibo, et al.
Publicado: (2020)

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
por: Pan, Cassie, et al.
Publicado: (2023)

Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta‐analysis
por: Li, Fan, et al.
Publicado: (2020)

Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study
por: Cui, Pengfei, et al.
Publicado: (2018)

Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study
por: Li, Xiaoyan, et al.
Publicado: (2022)

Prognostic value of lactate dehydrogenase in patients with uveal melanoma treated with immune checkpoint inhibition
por: Liang, Xiaocui, et al.
Publicado: (2023)

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy
por: Feng, Yangbo, et al.
Publicado: (2018)

Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases
por: Han, Jung Ho, et al.
Publicado: (2023)

Is preoperative serum lactate dehydrogenase useful in predicting the outcomes of patients with upper tract urothelial carcinoma?
por: Tan, Ping, et al.
Publicado: (2018)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
por: He, Man, et al.
Publicado: (2021)

Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy
por: Cheng, Mingxia, et al.
Publicado: (2022)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer
por: Aday, Ulaş, et al.
Publicado: (2020)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker
por: Fischer, Grant M., et al.
Publicado: (2020)

Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study
por: Ke, Linping, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
por: Qin, Angel, et al.
Publicado: (2016)

Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis
por: Zhang, Jiao, et al.
Publicado: (2015)

C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Wei, Yilun, et al.
Publicado: (2023)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zhang, Zhibo, et al.
Publicado: (2020)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhang, Yongchao, et al.
Publicado: (2022)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Sun, Li‐Yue, et al.
Publicado: (2021)

Comprehensive analysis of age‐related somatic mutation profiles in Chinese young lung adenocarcinoma patients
por: Yang, Bo, et al.
Publicado: (2019)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer
por: Deng, Taibing, et al.
Publicado: (2018)

Forward genetic screens identify mechanisms of resistance to small molecule lactate dehydrogenase inhibitors
por: Frank, Anderson R, et al.
Publicado: (2023)

Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
por: Park, Hyo Jung, et al.
Publicado: (2022)

The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
por: Zhang, Qianning, et al.
Publicado: (2022)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fski9f4ej4o7qm5isbsa149g8h